LC Sciences

LC Sciences is a global biotechnology company offering products and services to genomics and proteomics researchers in various markets for nucleic acid/protein analysis, biomarker discovery, and drug development. The company's portfolio includes innovative products and comprehensive services based on unique core technology platforms developed in-house. A wide range of microarray service products at LC Sciences are built on the µParaflo® microfluidic on-chip synthesis technology, enabling the provision of unique and customizable arrays of oligonucleotides, peptides, and analog molecules. The offerings encompass microRNA profiling, custom oligonucleotide (aptamer) screening, and peptide arrays for epitope mapping, protein kinase substrate profiling, and phosphopeptide binding assays. The company's OligoMix® technology has significantly reduced the cost and increased the speed of highly multiplexing genome-scale experiments like exploring small RNAs and designer gene/DNA library synthesis, as well as application to library construction of various biomolecules, sequence capture for targeted next-gen sequencing, and synthetic biology. The recently developed OligoFix™ strategy for the error correction of microarray-synthesized oligos has greatly improved the utility of OligoMix® for synthetic biology applications. Building on its innovative portfolio, LC Sciences also offers the game-changing VariantPro™ multiplex-PCR-based targeted sequencing system, providing a simple, robust process delivering cost savings due to improved sequencing efficiency. This system combines the specificity of a singleplex PCR reaction with the scalability of a multiplex reaction into a single step via relay-PCR, requiring less sequencing depth per sample. Founded in 2004, LC Sciences operates in the biotechnology and information technology industries. As of now, there is no publicly available information on the company's recent investments or its headquarters location.